David Preiss

10PUBLICATIONS
52CO-AUTHORS
Vision scienceOptical technologyMajor global burdens of diseaseBehavioural epidemiologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|May 12, 2026
Fenofibrate and progression of retinopathy in adults with diabetes: the randomised placebo-controlled LENS trial.

|Jul 03, 2025
Cost-effectiveness of fenofibrate versus standard care for reducing the progression of diabetic retinopathy: An economic evaluation based on data from the LENS trial.

Graham Scotland, Mekazin Tsehaye, Caroline Styles

|Apr 03, 2025
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.

Kaitlin J Mayne, Rebecca J Sardell, Natalie Staplin

|Oct 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

William G Herrington, Natalie Staplin, Nikita Agrawal

|Dec 12, 2023
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.

Kaitlin J Mayne, Natalie Staplin, David F Keane

|Sep 29, 2023
Quality of care for secondary cardiovascular disease prevention in 2009-2017: population-wide cohort study of antiplatelet therapy use in Scotland.

Inna Thalmann, David Preiss, Iryna Schlackow

Pageof 2

Frequent Collaborators

4 joint publications

Jonathan Emberson

4 joint publications

Katherine R Tuttle

3 joint publications

Parminder K Judge

3 joint publications

Richard Haynes